Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids

Table 6 Metabolomic HDL traits with an association with rs10911021 in diabetic participants

Trait (mol/l)	Number of non-T2D participants	Beta-effect in non-T2D participants (se)	p value	FDR adjusted p value	Number of T2D participants	Beta-effect in T2D participants (se)	p value	FDR adjusted p value	p value for conditional analysis with rs1689800	FDR adjusted p value for conditional analysis with rs1689800
Concentration of large HDL particles	5221	0.01 (0.02)	0.59	1	1310	−0.15 (0.04)	0.0005	0.03	0.001	0.07
Total lipids in large HDL	5229	0.01 (0.02)	0.62	1	1310	−0.15 (0.04)	0.0005	0.03	0.001	0.07
Phospholipids in large HDL	5223	0.01 (0.02)	0.59	1	1310	−0.14 (0.04)	0.0009	0.03	0.002	0.09
Total cholesterol in large HDL	5223	0.008 (0.02)	0.71	1	1310	−0.15 (0.04)	0.0004	0.04	0.001	0.07
Cholesterol esters in large HDL	5221	0.009 (0.02)	0.67	1	1310	−0.15 (0.04)	0.0004	0.03	0.001	0.07
Free cholesterol in large HDL	5221	0.005 (0.02)	0.83	1	1310	−0.16 (0.04)	0.0003	0.03	0.0009	0.07

Beta-effects corresponding to the minor allele are shown, along with the standard errors. FDR analysis was performed using the Benjamini-Hochberg-Yekutieli method. When the use of lipid lowering therapy was not included in the linear regression model, the results remained directionally similar, but the statistical significance of the effects was reduced
FDR false discovery rate

ISSN: 1475-2840